Sherry C. on
Sunday, November 30th, 2014
The final topic of discussion at this year’s 7th annual CTAD gathering was recent clinical research for treatment of the most troubling symptoms of Alzheimer’s disease. The presenter/author for this clinical trial was Rachelle S. Doody, MD, PhD, Director, Alzheimer’s disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX. The clinical trial involved development of AVP-923 (Dextromethorphan/Quinidine) for Pseudobulbar Affect (PBA) results from the Alzheimer’s Disease/Dementia Cohort of PRISM II.
Pseudobulbar Affect (PBA) is emotional lability which sometimes occurs as a symptom of neurologic disorder (such as Alzheimer’s disease) characterized by involuntary crying or uncontrollable episodes of crying and/or laughing, or other emotional outbursts.
The Prism study is a twelve week Phase 2 trial with patients presenting with various neurologic diseases including Alzheimer’s disease. The trial was initiated in order to observe the safety, tolerability and effectiveness of AVP—923 for PBA in those with dementia, traumatic brain injury or stroke. The initial outcome of the trial has shown that the drug significantly lowered PBA symptoms and it was tolerated well by participants in the study with dementia.
Other presenters at the CTAD gathered to discuss many other important new possibilities for new and better treatment of Alzheimer’s disease. To learn more about the full program you can view it online by going to go to www.ctad-alzheimer.com
Sherry C. on
Saturday, November 29th, 2014
Good news for Alzheimer’s prevention! At the 7th Annual International Conference on Clinical Trials for Alzheimer’s Disease (CTAD), a study was presented by Stephen Salloway, MD, MS, Director of Neurology and the Memory and Aging Program at Butler Hospital, Providence, RI, to evaluate amyloid PET imaging results. The study was initiated in order to evaluate the impact of Crenezumab on fibrillar amyloid in patients with mild-to-moderate Alzheimer’s disease. This topic was part of the mild to moderate Alzhiemer’s Prevention Clinical Research Initiative presented at this year’s annual conference.
The presenter discussed the latest clinical research findings on 2 different studies regarding an antibody called “crenezumab” which targets amyloid in the brain. The study evaluated several different methods of delivery of the antibody including: IV injections and subcutaneous (under the skin) administration. Three different tomography (PET) scans were taken during the trial to assess the change of amyloid level in the brain after the drug Crenezumab was given.
Another study that was discussed at the conference was presented by Presenters/Authors: R. Scott Turner, MD, Director, Memory Disorders Program, Georgetown University, Washington, DC. The study was conducted to evaluate whether Resveratrol was safe and well tolerated in mild to moderate Alzheimer’s disease (AD).
Resveratrol is a compound found in certain plants and in red wine that has antioxidant properties and has been investigated for possible ant- inflammatory and anti-cancer effects. This study shows some real promise that Resveratrol is well tolerated, passes through the blood-brain barrier, and may have a positive effect on some bio-markers of Alzheimer’s disease. Biomarkers are measurable substances whose presence may be an indication of a disease. Common biomarkers for AD include changes in cerebral spinal fluid and changes in tomography (PET) scans.
Sherry C. on
Tuesday, November 25th, 2014
First Category of Alzheimer’s Prevention Clinical Research Initiatives at the CTAD
The International Conference on Clinical Trials for Alzheimer’s Disease in Philadelphia, (also referred to as the CTAD) recently met to gather information regarding current research initiatives that indicate the highest level of promise for Alzheimer’s prevention and treatment.
PREVENTING ALZHEIMER’S BY TREATING EARLY
Presenters/Authors: Randall Bateman, MD, Charles F. and Joanne Knight Professor of Neurology, Washington University School of Medicine, St. Louis, MO presented information on a research project named, “The Collaboration for Alzheimer’s Prevention (CAP); Advancing the Evaluation of Alzheimer’s Prevention Therapies.”
This research project was established in order to ensure that the latest in cutting edge clinical trial information is available to the entire Alzheimer’s disease (AD) research field. CAP is sponsored by the Alzheimer’s Association and the Fidelity Biosciences Research Initiative. This project was launched in order to speed up the development of better and more effective AD treatments. Updates were provided on 4 AD prevention trials including: DIAN-TU, API, A4 and TOMMORROW-all trials test treatments that target a type of protein (called amyloid) that is deposited as plaque in the brain of those with AD.
Other Clinical Research Trials Presented at the CTAD
Philip Scheltens, MD, PhD, Professor of Cognitive Neurology and Director of the Alzheimer Center, VU University Medical Center in Amsterdam presented information on “Baseline Patient Characteristics from the Phase 3 SCarlet RoAD Trial, a Study of Gantenerumab in Patients with Prodromal AD.”
The SCarlet RoAD trial involving gantenerumab is a research project from the VU University Medical Center in Amsterdam. The trial was implemented in order to present initial clinical trial findings regarding 800 participants in the study with prodromal (early stage) AD who presented with memory loss and biomarker evidence of the disease (without any dementia).
Sherry C. on
Sunday, November 23rd, 2014
The International Conference on Clinical Trials for Alzheimer’s Disease in Philadelphia, (also referred to as the CTAD) recently met to gather information regarding current research initiatives showing the most promise for Alzheimer’s treatment and prevention.
The CTAD began in 2008 and since that time has continued its function to provide a platform for professional research experts from around the globe to come together in collaboration regarding research that may lead to new intervention and prevention modalities for AD. The disease effects 5.4 million people in American and nearly 36 million (with AD and related dementias) world-wide-and by the year 2050 that number is expected to grow to an astounding 115 million. In fact, if successful intervention is not achieved in the next 35 years, many experts project that Alzheimer’s disease may cost more than any other major illness in the healthcare industry-worldwide.
Top researchers around the globe came together for this year’s conference to discuss Alzheimer’s treatment and AD prevention and treatment clinical research trials that exhibit the most hope for the future. Other topics of discussion included-a strategy for new treatment alternatives for mild to moderate Alzheimer’s disease, as well as new drug treatment for some of the most disconcerting symptoms of the disease.
The conference was chaired by Paul Aisen, MD, University of California at San Diego; Bruno Vellas, MD, University of Toulouse; Jacques Touchon, MD, University of Montpellier; and Michael Weiner, MD, University of California at San Francisco.
According to the director of the Alzheimer’s Disease Cooperative Study (and Co-Organizer of the CTAD Conference), Paul Aisen, MD: “As evidenced by the research being presented this year, efforts to develop effective treatments for Alzheimer’s disease have been focused on the earliest stages of the disease, before symptoms are even apparent—but the needs of people already diagnosed have not been forgotten.”
The following topics discussed at the conference will be covered in subsequent blog entries:
Preventing Alzheimer’s By Treating Early
New Alzheimer’s Treatment Strategies for Mild to Moderate AD
Treating the most troubling symptoms in AD